NasdaqCM - Nasdaq Real Time Price USD

Aclarion, Inc. (ACON)

1.9500 -0.0200 (-1.02%)

At close: October 30 at 4:00:01 PM EDT

1.9314 -0.0186 (-0.95%)

After hours: October 30 at 6:29:19 PM EDT

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs

GlobeNewswire 9d ago

ACON
-1.02%
Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026

GlobeNewswire 11d ago

ACON
-1.02%
Aclarion to Present at the 20th Annual LD Micro Main Event

GlobeNewswire 18d ago

ACON
-1.02%
Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment

GlobeNewswire 23d ago

ACON
-1.02%
Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites

GlobeNewswire 1mo ago

ACON
-1.02%
Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site

GlobeNewswire 2mo ago

ACON
-1.02%
Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process

GlobeNewswire 2mo ago

ACON
-1.02%
Aclarion, Inc. (ACON) Reports Q2 Loss, Lags Revenue Estimates

Zacks 2mo ago

ACON
-1.02%
Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform

GlobeNewswire 4mo ago

ACON
-1.02%
Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal

GlobeNewswire 4mo ago

ACON
-1.02%
Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting

GlobeNewswire 4mo ago

ACON
-1.02%
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

GlobeNewswire 4mo ago

ACON
-1.02%

Performance Overview

Return	ACON	S&P 500 (^GSPC)
YTD	-57.61%	+10.73%
1-Year	-74.77%	+11.11%
3-Year	-100.00%	+81.91%

U.S. markets closed

Aclarion, Inc. (ACON)

Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs

Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026

Aclarion to Present at the 20th Annual LD Micro Main Event

Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment

Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites

Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site

Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process

Aclarion, Inc. (ACON) Reports Q2 Loss, Lags Revenue Estimates

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform

Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal

Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting

Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation